While colorectal cancer polyps often have no symptoms—especially in the early stages—there are some warning signs to be on ...

Adult patients with severe CRSwNP treated with tezepelumab continued to receive benefit 24 weeks after treatment cessation.

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

Nasacort takes up to a week to achieve full benefits for allergy symptoms, and should be used daily for optimal allergy relief. Here's what you need to know about the safety and risks of using this ...

The progression of colorectal cancer (CRC) is an intriguing though somewhat complex process, but understanding it is crucial to appreciate why this disease must never be underestimated. It also ...

CRSwNP affects approximately 320 million people worldwide. The condition causes benign polyp growths in the nasal cavity and symptoms including congestion and reduced sense of smell. Current therapies ...

Tezspire (tezepelumab-ekko) is a prescription medicine used to treat inflammatory conditions of the airways, such as severe asthma. The FDA has now approved it as an add-on treatment for adults and ...

Tezepelumab-ekko is now approved for chronic rhinosinusitis with nasal polyps (CRSwNP), targeting thymic stromal lymphopoietin and marking its second indication after severe asthma. The phase 3 ...

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with nasal polyps (CRSwNP), a second biologic therapy has broken through with a ...

AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately ...

THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE ® (tezepelumab-ekko) for the ...

Please provide your email address to receive an email when new articles are posted on . The FDA on Friday approved a new biologic as add-on maintenance treatment for inadequately controlled chronic ...